Drug Shortage Report for DALACIN C 300 MG
| Report ID | 118995 |
| Drug Identification Number | 02182866 |
| Brand name | DALACIN C 300 MG |
| Common or Proper name | DALACIN C 300MG |
| Company Name | PFIZER CANADA ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | CLINDAMYCIN |
| Strength(s) | 300MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 100 BTL |
| ATC code | J01FF |
| ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-06-30 |
| Estimated end date | |
| Actual end date | 2020-08-25 |
| Shortage status | Resolved |
| Updated date | 2020-08-26 |
| Company comments | |
| Health Canada comments | |
| Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.